Literature DB >> 9016707

CD22 is a negative regulator of B-cell receptor signalling.

L Nitschke1, R Carsetti, B Ocker, G Köhler, M C Lamers.   

Abstract

BACKGROUND: . Antibody responses are triggered by binding of antigen to the B-cell antigen receptor (BCR). The strength of the resulting signal determines the outcome of the response, which may vary from the induction of tolerance to the antigen, to the production of specific high-affinity antibodies. Additional cell-surface proteins assist the BCR in its function, and can facilitate or inhibit an antibody response. CD22 is a BCR-associated transmembrane protein, the cytoplasmic tail of which contains three immunoreceptor tyrosine-based inhibitory motifs. These motifs are phosphorylated upon BCR-crosslinking, and can bind the tyrosine phosphatase SHP-1, a putative negative regulator of signalling from the BCR. In order to assess the role of CD22 in vivo, we have generated CD22(-/-) mice by targeted gene inactivation.
RESULTS: . In CD22(-/-) mice, B-cell development is normal. There are normal numbers of peripheral B cells, but these have a more mature phenotype. In addition, recirculating B cells are absent from the bone marrow. However, the distribution of the two B-cell subtypes, B-1 and B-2, is normal. After BCR-crosslinking in vitro, splenic CD22(-/-) B cells show an increased Ca2+ influx and a lower survival due to an increased induction of apoptosis. In contrast, there is an increased proliferative response to the B-cell mitogen lipopolysaccharide (LPS). A shorter average lifespan in the B-cell compartment is also found in vivo. Furthermore, T-cell independent immune responses are impaired, whereas T-cell dependent responses are normal.
CONCLUSIONS: . The absence of CD22 expression lowers the signalling threshold for BCR-crosslinking and can thus influence the fate of the B cell. We propose that the low threshold leads to hyperresponsiveness of the B cells and a chronic basal activation. In this model, engagement of the receptor without T-cell help leads to an increased induction of apoptosis, thus explaining the shorter lifespan of CD22(-/-) B cells and the low response to T-cell independent antigens. The alteration in B-cell phenotype and the higher levels of LPS-reactivity are attributable to the chronic basal stimulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9016707     DOI: 10.1016/s0960-9822(06)00057-1

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  118 in total

1.  Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor.

Authors:  J Munday; S Kerr; J Ni; A L Cornish; J Q Zhang; G Nicoll; H Floyd; M G Mattei; P Moore; D Liu; P R Crocker
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

2.  B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.

Authors:  F Loder; B Mutschler; R J Ray; C J Paige; P Sideras; R Torres; M C Lamers; R Carsetti
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

Review 3.  Siglecs in the immune system.

Authors:  P R Crocker; A Varki
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

Review 4.  Positive and negative roles of CD72 in B cell function.

Authors:  Hsin-Jung Wu; Subbarao Bondada
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  N-Glycan Branching Is Required for Development of Mature B Cells.

Authors:  Christie-Lynn Mortales; Sung-Uk Lee; Michael Demetriou
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

Review 6.  Models of signal transduction through the B-cell antigen receptor.

Authors:  Roland Geisberger; Reto Crameri; Gernot Achatz
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

Review 7.  Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

Authors:  Huan Cao; Paul R Crocker
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

8.  Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling.

Authors:  Francesca Gasparrini; Christoph Feest; Andreas Bruckbauer; Pieta K Mattila; Jennifer Müller; Lars Nitschke; Dennis Bray; Facundo D Batista
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

9.  Skewed B cell differentiation affects lymphoid organogenesis but not T cell-mediated autoimmunity.

Authors:  E Colombo; P Tentorio; S Musio; K Rajewsky; R Pedotti; S Casola; C Farina
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

Review 10.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.